top of page
Browse by category
Search
AI-powered smartphone app constructs 3D model to accurately predict body fat
Researchers from the University of Cambridge have developed a smartphone app that uses machine learning to accurately determine body...
United Biotechnology and Novo Nordisk agree license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The United Laboratories International Holdings Limited’s (TUL) wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd....
Improving GLP-1 drug delivery by fusing the peptide directly to immunoglobulin antibodies
Massachusetts Institute of Technology (MIT) researchers have revealed a drug delivery system that "paints" glucagon-like peptide-1...
OAC and TOS urge FDA to enforce GLP-1s compounding regulations
The Obesity Action Coalition (OAC) and The Obesity Society (TOS) have sent a letter to the FDA, along with more than 20 leading...
Combination of the Allurion Program with low-dose GLP-1 therapy to optimise muscle mass and GLP-1 adherence
Allurion Technologies has announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimise...
Why women experience stronger side effects from GLP-1s
There are fundamental sex-based differences in how weight loss medications interact with human biology, according to a study by Olio...
Browse by tag
bottom of page